1. Home
  2. SPRO vs CCLD Comparison

SPRO vs CCLD Comparison

Compare SPRO & CCLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.35

Market Cap

136.7M

Sector

Health Care

ML Signal

HOLD

Logo CareCloud Inc.

CCLD

CareCloud Inc.

HOLD

Current Price

$3.33

Market Cap

133.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPRO
CCLD
Founded
2013
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
136.7M
133.1M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
SPRO
CCLD
Price
$2.35
$3.33
Analyst Decision
Buy
Hold
Analyst Count
2
1
Target Price
$5.00
$1.50
AVG Volume (30 Days)
372.1K
345.8K
Earning Date
11-13-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.08
Revenue
$40,549,000.00
$114,315,000.00
Revenue This Year
N/A
$8.58
Revenue Next Year
N/A
$12.06
P/E Ratio
N/A
$43.48
Revenue Growth
N/A
2.97
52 Week Low
$0.51
$1.14
52 Week High
$3.22
$4.75

Technical Indicators

Market Signals
Indicator
SPRO
CCLD
Relative Strength Index (RSI) 51.50 60.88
Support Level $2.26 $3.04
Resistance Level $2.39 $3.35
Average True Range (ATR) 0.09 0.12
MACD -0.00 0.04
Stochastic Oscillator 70.83 96.15

Price Performance

Historical Comparison
SPRO
CCLD

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About CCLD CareCloud Inc.

CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.

Share on Social Networks: